Log inSign up
Image
user avatar
David Russler-Germain, MD/PhD
@dgermain21
Oncology Instructor @SitemanCenter @WUSTLmed | lymphoma/leukemia researcher @LabFehniger | all views 100% my own
St. Louis, MO
Joined January 2009
898
Following
3,809
Followers
  • Pinned
    user avatar
    David Russler-Germain, MD/PhD
    @dgermain21
    Jul 3, 2023
    Pretty much everyone who knows me knows I'm a big fan of bispecific antibodies for B-NHL. For a summary of key landmarks in this space, emerging evidence and lessons from recent clinical trials, and exciting new directions, check out our review:
    Image
    Frontiers | T-cell redirecting therapies for B-cell non-Hodgkin lymphoma: recent progress and...
    From frontiersin.org
    23K
  • user avatar
    David Russler-Germain, MD/PhD
    @dgermain21
    Feb 1, 2022
    Literally the last paragraph of the article reads:
    Image
    user avatar
    The New York Times
    @nytimes
    Feb 1, 2022
    Breaking News: Pfizer and its partner BioNTech are expected to ask the FDA as soon as Tuesday to authorize its Covid vaccine for children 6 months to 4 years old as a two-dose regimen. nyti.ms/3oALCR9
  • user avatar
    David Russler-Germain, MD/PhD
    @dgermain21
    Jun 21, 2022
    How do I teach the essentials of DLBCL to my co-fellows? See this folder for my slide-deck and PDFs of the references. Enjoy! wustl.box.com/s/k076bndfpjh0…
  • user avatar
    David Russler-Germain, MD/PhD
    @dgermain21
    Jan 20, 2023
    I'm prepping a talk and for the first time it dawned on me: why don't I put a QR code at the end that links to a Box drive folder of the PDFs of every reference I cited in the talk? Cool or dumb idea? Seems super obvious now...
    51K
  • user avatar
    David Russler-Germain, MD/PhD
    @dgermain21
    Apr 21, 2021
    If I had to give future heme/onc fellows one piece of advice not directly related to patient care, it'd be to read at 1+ paper every (week)day. Set aside 30 min to read something from NEJM, Lancet, JAMA, Blood, JCO, or any sub-journal. Save and highlight PDFs digitally.
  • user avatar
    David Russler-Germain, MD/PhD
    @dgermain21
    Jun 8, 2022
    So was I last person on earth to learn that NCI-designated cancer centers don’t have to accept Medicaid? Heard from few fellows at ASCO from other institutions (some of which I thought were safety-nets) that their cancer centers won’t treat patients on Medicaid. Help me process…
  • user avatar
    David Russler-Germain, MD/PhD
    @dgermain21
    Apr 27, 2022
    I’m honored to receive a 2022 LRF Postdoctoral Fellowship to support my work in @LabFehniger on lymphoma mouse models of FL/DLBCL. Many thanks to everyone supporting my physician-scientist training: Todd, Tim Ley, @nancybartlettMD, @KahlBrad, @DiPersioLab, and many others!
    user avatar
    Lymphoma Research Foundation
    @lymphoma
    Apr 27, 2022
    We are pleased to announce the 2022 LRF grantee class, with $5.7 million in grants awarded to early career and established scientists working on innovative lymphoma research. Read more about our grantees by visiting us at lymphoma.org/news/2022grant….
  • user avatar
    David Russler-Germain, MD/PhD
    @dgermain21
    Sep 16, 2023
    CART cells are revolutionizing B-NHL treatment. But… Let’s not sweep under the rug: (1) ~$400k product, ~$1M “total package” (2) ~1/4 patients required ICU care (3) Non-relapse mortality ~10% We need to acknowledge the downsides to make CART cells cheaper, faster, and safer.
    user avatar
    Eddie Cliff
    @Eddie_Cliff
    Sep 15, 2023
    The ALYCANTE trial of axi-cel in transplant ineligible DLBCL patients just out in @NatureMedicine 88.7% patients over the age of 65 Median PFS 11.8 months Grade 3/4 CRS 8.1% Grade 3/4 ICANS/neuro events 14.5% #lymsm
    43K
  • user avatar
    David Russler-Germain, MD/PhD
    @dgermain21
    Nov 6, 2022
    I’ve been asked to re-share some of my lymphoma teaching resources from @WUHemeOncFellow. So glad people find them useful! Focused review of RT for DLBCL: wustl.box.com/s/u04583yxw92e… Broad review of DLBCL for first year fellows: wustl.box.com/s/ekrn9y9rka1c…
  • user avatar
    David Russler-Germain, MD/PhD
    @dgermain21
    Jun 22, 2021
    Recently saw a patient for “new MDS” with Celiac dz, a prior small bowel resection, and was taking two zinc-containing supplements. Negative sequencing and FISH. Copper level below limit of detection, zinc level 3x ULN. IV cupric chloride to the rescue! Normal CBC now!
    This Post is from an account that no longer exists. Learn more
  • user avatar
    David Russler-Germain, MD/PhD
    @dgermain21
    Sep 30, 2022
    The @nytimes does a great job covering legitimate amazingness of CAR-T cell therapy for cancer. But they should follow-up those pieces with a series on how poorly insurance companies are behaving as they delay patients' access to this treatment for months without justification.
  • user avatar
    David Russler-Germain, MD/PhD
    @dgermain21
    Nov 5, 2023
    Replying to @VPrasadMDMPH
    Be the doctor you want taking care of your family members. Hard for that advice to lead you astray.
    4.1K
  • user avatar
    David Russler-Germain, MD/PhD
    @dgermain21
    Jan 5, 2021
    Sometimes I read prominent papers and I think, "What in the world is going on here? Why am I so confused?" Recently, I'm realizing it's because it's easy for authors to obfuscate the data and make plots of p-values instead of actual data. I'm staring at bar charts...of p-values.
  • user avatar
    David Russler-Germain, MD/PhD
    @dgermain21
    Oct 12, 2023
    After the polatuzumab ODAC, @Eddie_Cliff and I were very intrigued by the POLARIX subgroup analyses. This led to multiple discussions, and together with @nancybartlettMD, we've published our impressions of the polatuzumab COO interaction: ashpublications.org/blood/article/… #lymsm
    15K